Oncology & Cancer

Next-gen melanoma drug, TAK-733, excels in lab tests

A University of Colorado Cancer Center study published online this week in the journal Molecular Cancer Therapeutics reports anti-cancer activity in 10 out of 11 patient tumor samples grown in mice and treated with the experimental ...

Oncology & Cancer

The role of fibronectin in BRAF-mutant thyroid cancer treatment

New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, Ph.D., could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene—a mutation also ...

page 3 from 5